Urology in the elderly
Poster Session 83

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 3
Chairs: T. Antunes Lopes, Porto (PT)
S. Arlandis Guzman, Valencia (ES)
D. Bratuš, Maribor (SI)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1153

The impact of frailty gap on prognosis in patients with urological cancers: A comparison of community-dwelling population

By: Soma O. 1, Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Koie T. 2, Ohyma C. 1
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Gifu University School of Medicine, Dept. of Urology, Gifu, Japan

1154

Pre-operative risk assessment by ASA score and modified Frailty Index (mFI) in oncological and non oncological urological surgery

By: Serretta V. 1, Muffoletto F. 1, Tulone G. 1, Dioguardi S. 1, Guzzardo C. 1, Billeci S. 1, Baiamonte D. 1, Giannone S. 1, Sanfilippo C. 2, Scalici Gesolfo C. 3, Simonato A. 1
1University of Palermo, Section of Urology, Dept. of Surgical, Oncological and Oral Sciences, Palermo, Italy,
2GSTU Foundation, Statistics, Palermo, Italy,
3Paolo Borsellino Hospital, Dept. of Urology, Marsala, Italy

1155

Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy

By: Teishima J. 1, Mita K. 2, Shigeta M. 3, Hasegawa Y. 4, Kadonishi Y. 5, Inoue S. 1, Hayashi T. 1, Matsubara A. 1
1Hiroshima University, Dept. of Urology, Hiroshima, Japan,
2Hiroshima City Asa Citizens Hospital, Dept. of Urology, Hiroshima, Japan,
3Kure Medical Center and Chugoku Cancer Center, Dept. of Urology, Kure, Japan,
4Fukuyama Medical Center, Dept. of Urology, Fukuyama, Japan,
5Onomichi General Hospital, Dept. of Urology, Onomichi, Japan

1156

Non-muscle invasive urothelial bladder cancer (NMIBC) in very elderly patients: What does affect overall survival (OS)? Clinical outcomes in a retrospective analysis

By: Di Cosmo G., Verzotti E., Pavan N., Silvestri T., Boschin R., Liguori G.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1157</td>
<td>Comparison of outcomes between standard and palliative management for high grade non-muscle invasive bladder cancer in patients older than 85 years</td>
<td>Carrión Puig A., Diaz F., Raventos C., Lozano F., Miret E., Cuadras M., Morote J. Hospital Vall Hebron, Dept. of Urology, Barcelona, Spain</td>
</tr>
<tr>
<td>1159</td>
<td>Perioperative parameters and prognosis analysis of patients aged 80 years old or older treated with radical prostatectomy for prostate cancer</td>
<td>Zhang F., Huang Y., Ma L. Peking University Third Hospital, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>1160</td>
<td>The role of G8 screening tool in the assessment of surgical outcome of elderly patients (≥75 y.o.) with high-risk prostate cancer: A pilot study</td>
<td>Matsushita K., Sandhu J.S., Horie S., Endo F., Shimbo M., Narimoto K., Hattori K. Juntendo University, Dept. of Urology, Tokyo, Japan, Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan</td>
</tr>
<tr>
<td>1162</td>
<td>The impact of fall on nocturia and frailty in community-dwelling individuals</td>
<td>Hatakeyama S., Imai A., Yamamoto H., Matsumoto T., Soma O., Yoneyama T., Hashimoto Y., Nakaji S., Ohyama C. Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Social Medicine, Hirosaki, Japan</td>
</tr>
<tr>
<td>1163</td>
<td>Benign prostatic hyperplasia increases the risk of Parkinson’s disease: A population-based study</td>
<td>Chan J.K.S., Shih H.J., Huang C.J. Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan</td>
</tr>
<tr>
<td>1165</td>
<td>Effect of mirabegron on cognitive function in elderly patients with overactive bladder: Results from a phase 4 placebo-controlled study (PILLAR)</td>
<td></td>
</tr>
</tbody>
</table>
By: Griebling T.L.1, Campbell N.2, Mangel J.3, Staskin D.4, Herschorn S.5, Elsouda D.6, Schermer C.6

1The University of Kansas, Dept. of Urology and The Landon Center on Aging, Kansas City, Kansas, United States of America, 2Purdue University, College of Pharmacy and Indiana University, Center for Aging Research, Lafayette and Indianapolis, Indiana, United States of America, 3MetroHealth Medical Center, Division of Urogynaecology and Pelvic Reconstructive Surgery, Cleveland, Ohio, United States of America, 4St. Elizabeth’s Medical Center, Division of Urology, Boston, Massachusetts, United States of America, 5Sunnybrook Health Sciences Centre, University of Toronto, Division of Urology, Toronto, Ontario, Canada, 6Astellas Pharma Global Development, Inc., Medical Affairs, Northbrook, Illinois, United States of America

1166

Strategies to safely treat OAB in the elderly based on comorbidity, comedication and risks of serious adverse events

By: Martens F.M.J., De Wall L.L., Heesakkers J.P.F.A.
Radboudumc, Dept. of Urology, Nijmegen, The Netherlands